 | • レポートコード：GIR201106039 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、137ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、乏突起神経膠腫治療の世界市場を調査対象にし、乏突起神経膠腫治療の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（アリサチブ、ベバシズマブ、CDX-1401、ダサチニブ、DCVax-L、IMA-950、その他）、用途別分析（クリニック、病院、ASC）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：AngioChem Inc、Immatics Biotechnologies GmbH、Cavion LLC、Boehringer Ingelheim GmbH、F. Hoffmann-La Roche Ltd、Bristol-Myers Squibb Co、Leadiant Biosciences Inc、Eli Lilly and Co、Celldex Therapeutics Inc、Ipsen SA、Tocagen Inc、Millennium Pharmaceuticals Inc、Pfizer Inc、Northwest Biotherapeutics Inc、Novartis AG ・メーカー別販売量、売上、市場シェア ・乏突起神経膠腫治療の地域別市場分析 ・乏突起神経膠腫治療の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・乏突起神経膠腫治療のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・乏突起神経膠腫治療のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・乏突起神経膠腫治療の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・乏突起神経膠腫治療の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・乏突起神経膠腫治療の種類別市場規模2015-2020：アリサチブ、ベバシズマブ、CDX-1401、ダサチニブ、DCVax-L、IMA-950、その他 ・乏突起神経膠腫治療の用途別市場規模2015-2020：クリニック、病院、ASC ・乏突起神経膠腫治療の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Oligodendroglioma Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Oligodendroglioma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Oligodendroglioma Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Oligodendroglioma Treatment market has been segmented into
Alisertib
Bevacizumab
CDX-1401
Dasatinib
DCVax-L
IMA-950
Others
By Application, Oligodendroglioma Treatment has been segmented into:
Clinic
Hospital
ASCs
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Oligodendroglioma Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Oligodendroglioma Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Oligodendroglioma Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Oligodendroglioma Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Oligodendroglioma Treatment Market Share Analysis
Oligodendroglioma Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Oligodendroglioma Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Oligodendroglioma Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Oligodendroglioma Treatment are:
AngioChem Inc
Immatics Biotechnologies GmbH
Cavion LLC
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Co
Leadiant Biosciences Inc
Eli Lilly and Co
Celldex Therapeutics Inc
Ipsen SA
Tocagen Inc
Millennium Pharmaceuticals Inc
Pfizer Inc
Northwest Biotherapeutics Inc
Novartis AG
Among other players domestic and global, Oligodendroglioma Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oligodendroglioma Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oligodendroglioma Treatment, with price, sales, revenue and global market share of Oligodendroglioma Treatment in 2018 and 2019.
Chapter 3, the Oligodendroglioma Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oligodendroglioma Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Oligodendroglioma Treatment market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Oligodendroglioma Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Oligodendroglioma Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oligodendroglioma Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Alisertib
1.2.3 Bevacizumab
1.2.4 CDX-1401
1.2.5 Dasatinib
1.2.6 DCVax-L
1.2.7 IMA-950
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Oligodendroglioma Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Clinic
1.3.3 Hospital
1.3.4 ASCs
1.4 Overview of Global Oligodendroglioma Treatment Market
1.4.1 Global Oligodendroglioma Treatment Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AngioChem Inc
2.1.1 AngioChem Inc Details
2.1.2 AngioChem Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AngioChem Inc SWOT Analysis
2.1.4 AngioChem Inc Product and Services
2.1.5 AngioChem Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Immatics Biotechnologies GmbH
2.2.1 Immatics Biotechnologies GmbH Details
2.2.2 Immatics Biotechnologies GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Immatics Biotechnologies GmbH SWOT Analysis
2.2.4 Immatics Biotechnologies GmbH Product and Services
2.2.5 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Cavion LLC
2.3.1 Cavion LLC Details
2.3.2 Cavion LLC Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Cavion LLC SWOT Analysis
2.3.4 Cavion LLC Product and Services
2.3.5 Cavion LLC Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Boehringer Ingelheim GmbH
2.4.1 Boehringer Ingelheim GmbH Details
2.4.2 Boehringer Ingelheim GmbH Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Boehringer Ingelheim GmbH SWOT Analysis
2.4.4 Boehringer Ingelheim GmbH Product and Services
2.4.5 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 F. Hoffmann-La Roche Ltd
2.5.1 F. Hoffmann-La Roche Ltd Details
2.5.2 F. Hoffmann-La Roche Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 F. Hoffmann-La Roche Ltd SWOT Analysis
2.5.4 F. Hoffmann-La Roche Ltd Product and Services
2.5.5 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bristol-Myers Squibb Co
2.6.1 Bristol-Myers Squibb Co Details
2.6.2 Bristol-Myers Squibb Co Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Bristol-Myers Squibb Co SWOT Analysis
2.6.4 Bristol-Myers Squibb Co Product and Services
2.6.5 Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Leadiant Biosciences Inc
2.7.1 Leadiant Biosciences Inc Details
2.7.2 Leadiant Biosciences Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Leadiant Biosciences Inc SWOT Analysis
2.7.4 Leadiant Biosciences Inc Product and Services
2.7.5 Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Eli Lilly and Co
2.8.1 Eli Lilly and Co Details
2.8.2 Eli Lilly and Co Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Eli Lilly and Co SWOT Analysis
2.8.4 Eli Lilly and Co Product and Services
2.8.5 Eli Lilly and Co Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Celldex Therapeutics Inc
2.9.1 Celldex Therapeutics Inc Details
2.9.2 Celldex Therapeutics Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Celldex Therapeutics Inc SWOT Analysis
2.9.4 Celldex Therapeutics Inc Product and Services
2.9.5 Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Ipsen SA
2.10.1 Ipsen SA Details
2.10.2 Ipsen SA Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Ipsen SA SWOT Analysis
2.10.4 Ipsen SA Product and Services
2.10.5 Ipsen SA Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Tocagen Inc
2.11.1 Tocagen Inc Details
2.11.2 Tocagen Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Tocagen Inc SWOT Analysis
2.11.4 Tocagen Inc Product and Services
2.11.5 Tocagen Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Millennium Pharmaceuticals Inc
2.12.1 Millennium Pharmaceuticals Inc Details
2.12.2 Millennium Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Millennium Pharmaceuticals Inc SWOT Analysis
2.12.4 Millennium Pharmaceuticals Inc Product and Services
2.12.5 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Pfizer Inc
2.13.1 Pfizer Inc Details
2.13.2 Pfizer Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Pfizer Inc SWOT Analysis
2.13.4 Pfizer Inc Product and Services
2.13.5 Pfizer Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Northwest Biotherapeutics Inc
2.14.1 Northwest Biotherapeutics Inc Details
2.14.2 Northwest Biotherapeutics Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Northwest Biotherapeutics Inc SWOT Analysis
2.14.4 Northwest Biotherapeutics Inc Product and Services
2.14.5 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 Novartis AG
2.15.1 Novartis AG Details
2.15.2 Novartis AG Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Novartis AG SWOT Analysis
2.15.4 Novartis AG Product and Services
2.15.5 Novartis AG Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Oligodendroglioma Treatment Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Oligodendroglioma Treatment Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Oligodendroglioma Treatment Manufacturer Market Share in 2019
3.3.2 Top 6 Oligodendroglioma Treatment Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Oligodendroglioma Treatment Sales, Revenue and Market Share by Regions
4.1.1 Global Oligodendroglioma Treatment Sales and Market Share by Regions (2015-2020)
4.1.2 Global Oligodendroglioma Treatment Revenue and Market Share by Regions (2015-2020)
4.2 North America Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
4.3 Europe Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
4.5 South America Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Oligodendroglioma Treatment Sales, Revenue and Market Share by Country
5.1.1 North America Oligodendroglioma Treatment Sales and Market Share by Country (2015-2020)
5.1.2 North America Oligodendroglioma Treatment Revenue and Market Share by Country (2015-2020)
5.2 United States Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
5.3 Canada Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
5.4 Mexico Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Oligodendroglioma Treatment Sales, Revenue and Market Share by Country
6.1.1 Europe Oligodendroglioma Treatment Sales and Market Share by Country (2015-2020)
6.1.2 Europe Oligodendroglioma Treatment Revenue and Market Share by Country (2015-2020)
6.2 Germany Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
6.3 UK Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
6.4 France Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
6.5 Russia Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
6.6 Italy Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Oligodendroglioma Treatment Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Oligodendroglioma Treatment Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Oligodendroglioma Treatment Revenue and Market Share by Regions (2015-2020)
7.2 China Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
7.3 Japan Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
7.4 Korea Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
7.5 India Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
7.7 Australia Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Oligodendroglioma Treatment Sales, Revenue and Market Share by Country
8.1.1 South America Oligodendroglioma Treatment Sales and Market Share by Country (2015-2020)
8.1.2 South America Oligodendroglioma Treatment Revenue and Market Share by Country (2015-2020)
8.2 Brazil Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
8.3 Argentina Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Oligodendroglioma Treatment Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Oligodendroglioma Treatment Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Oligodendroglioma Treatment Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
9.3 Turkey Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
9.4 Egypt Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
9.5 South Africa Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Oligodendroglioma Treatment Sales and Market Share by Type (2015-2020)
10.2 Global Oligodendroglioma Treatment Revenue and Market Share by Type (2015-2020)
10.3 Global Oligodendroglioma Treatment Price by Type (2015-2020)
11 Global Oligodendroglioma Treatment Market Segment by Application
11.1 Global Oligodendroglioma Treatment Sales Market Share by Application (2015-2020)
11.2 Global Oligodendroglioma Treatment Revenue Market Share by Application (2015-2020)
11.3 Global Oligodendroglioma Treatment Price by Application (2015-2020)
12 Market Forecast
12.1 Global Oligodendroglioma Treatment Sales, Revenue and Growth Rate (2021-2025)
12.2 Oligodendroglioma Treatment Market Forecast by Regions (2021-2025)
12.2.1 North America Oligodendroglioma Treatment Market Forecast (2021-2025)
12.2.2 Europe Oligodendroglioma Treatment Market Forecast (2021-2025)
12.2.3 Asia-Pacific Oligodendroglioma Treatment Market Forecast (2021-2025)
12.2.4 South America Oligodendroglioma Treatment Market Forecast (2021-2025)
12.2.5 Middle East & Africa Oligodendroglioma Treatment Market Forecast (2021-2025)
12.3 Oligodendroglioma Treatment Market Forecast by Type (2021-2025)
12.3.1 Global Oligodendroglioma Treatment Sales Forecast by Type (2021-2025)
12.3.2 Global Oligodendroglioma Treatment Market Share Forecast by Type (2021-2025)
12.4 Oligodendroglioma Treatment Market Forecast by Application (2021-2025)
12.4.1 Global Oligodendroglioma Treatment Sales Forecast by Application (2021-2025)
12.4.2 Global Oligodendroglioma Treatment Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Oligodendroglioma Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Oligodendroglioma Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Oligodendroglioma Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. AngioChem Inc Basic Information, Manufacturing Base and Competitors
Table 8. AngioChem Inc Oligodendroglioma Treatment Major Business
Table 9. AngioChem Inc Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 10. AngioChem Inc SWOT Analysis
Table 11. AngioChem Inc Oligodendroglioma Treatment Product and Services
Table 12. AngioChem Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Immatics Biotechnologies GmbH Basic Information, Manufacturing Base and Competitors
Table 14. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Major Business
Table 15. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 16. Immatics Biotechnologies GmbH SWOT Analysis
Table 17. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product and Services
Table 18. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Cavion LLC Basic Information, Manufacturing Base and Competitors
Table 20. Cavion LLC Oligodendroglioma Treatment Major Business
Table 21. Cavion LLC Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 22. Cavion LLC SWOT Analysis
Table 23. Cavion LLC Oligodendroglioma Treatment Product and Services
Table 24. Cavion LLC Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 26. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Major Business
Table 27. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 28. Boehringer Ingelheim GmbH SWOT Analysis
Table 29. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product and Services
Table 30. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 32. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Major Business
Table 33. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 34. F. Hoffmann-La Roche Ltd SWOT Analysis
Table 35. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product and Services
Table 36. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Bristol-Myers Squibb Co Basic Information, Manufacturing Base and Competitors
Table 38. Bristol-Myers Squibb Co Oligodendroglioma Treatment Major Business
Table 39. Bristol-Myers Squibb Co Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 40. Bristol-Myers Squibb Co SWOT Analysis
Table 41. Bristol-Myers Squibb Co Oligodendroglioma Treatment Product and Services
Table 42. Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Leadiant Biosciences Inc Basic Information, Manufacturing Base and Competitors
Table 44. Leadiant Biosciences Inc Oligodendroglioma Treatment Major Business
Table 45. Leadiant Biosciences Inc Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 46. Leadiant Biosciences Inc SWOT Analysis
Table 47. Leadiant Biosciences Inc Oligodendroglioma Treatment Product and Services
Table 48. Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Eli Lilly and Co Basic Information, Manufacturing Base and Competitors
Table 50. Eli Lilly and Co Oligodendroglioma Treatment Major Business
Table 51. Eli Lilly and Co Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 52. Eli Lilly and Co SWOT Analysis
Table 53. Eli Lilly and Co Oligodendroglioma Treatment Product and Services
Table 54. Eli Lilly and Co Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Celldex Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 56. Celldex Therapeutics Inc Oligodendroglioma Treatment Major Business
Table 57. Celldex Therapeutics Inc Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 58. Celldex Therapeutics Inc SWOT Analysis
Table 59. Celldex Therapeutics Inc Oligodendroglioma Treatment Product and Services
Table 60. Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Ipsen SA Basic Information, Manufacturing Base and Competitors
Table 62. Ipsen SA Oligodendroglioma Treatment Major Business
Table 63. Ipsen SA Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 64. Ipsen SA SWOT Analysis
Table 65. Ipsen SA Oligodendroglioma Treatment Product and Services
Table 66. Ipsen SA Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Tocagen Inc Basic Information, Manufacturing Base and Competitors
Table 68. Tocagen Inc Oligodendroglioma Treatment Major Business
Table 69. Tocagen Inc Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 70. Tocagen Inc SWOT Analysis
Table 71. Tocagen Inc Oligodendroglioma Treatment Product and Services
Table 72. Tocagen Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Millennium Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 74. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Major Business
Table 75. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 76. Millennium Pharmaceuticals Inc SWOT Analysis
Table 77. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product and Services
Table 78. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 80. Pfizer Inc Oligodendroglioma Treatment Major Business
Table 81. Pfizer Inc Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 82. Pfizer Inc SWOT Analysis
Table 83. Pfizer Inc Oligodendroglioma Treatment Product and Services
Table 84. Pfizer Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Northwest Biotherapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 86. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Major Business
Table 87. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 88. Northwest Biotherapeutics Inc SWOT Analysis
Table 89. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product and Services
Table 90. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 92. Novartis AG Oligodendroglioma Treatment Major Business
Table 93. Novartis AG Oligodendroglioma Treatment Total Revenue (USD Million) (2018-2019)
Table 94. Novartis AG SWOT Analysis
Table 95. Novartis AG Oligodendroglioma Treatment Product and Services
Table 96. Novartis AG Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. Global Oligodendroglioma Treatment Sales by Manufacturer (2018-2019) (K Pcs)
Table 98. Global Oligodendroglioma Treatment Revenue by Manufacturer (2018-2019) (USD Million)
Table 99. Global Oligodendroglioma Treatment Sales by Regions (2015-2020) (K Pcs)
Table 100. Global Oligodendroglioma Treatment Sales Market Share by Regions (2015-2020)
Table 101. Global Oligodendroglioma Treatment Revenue by Regions (2015-2020) (USD Million)
Table 102. North America Oligodendroglioma Treatment Sales by Countries (2015-2020) (K Pcs)
Table 103. North America Oligodendroglioma Treatment Sales Market Share by Countries (2015-2020)
Table 104. North America Oligodendroglioma Treatment Revenue by Countries (2015-2020) (USD Million)
Table 105. North America Oligodendroglioma Treatment Revenue Market Share by Countries (2015-2020)
Table 106. Europe Oligodendroglioma Treatment Sales by Countries (2015-2020) (K Pcs)
Table 107. Europe Oligodendroglioma Treatment Sales Market Share by Countries (2015-2020)
Table 108. Europe Oligodendroglioma Treatment Revenue by Countries (2015-2020) (USD Million)
Table 109. Asia-Pacific Oligodendroglioma Treatment Sales by Regions (2015-2020) (K Pcs)
Table 110. Asia-Pacific Oligodendroglioma Treatment Sales Market Share by Regions (2015-2020)
Table 111. Asia-Pacific Oligodendroglioma Treatment Revenue by Regions (2015-2020) (USD Million)
Table 112. South America Oligodendroglioma Treatment Sales by Countries (2015-2020) (K Pcs)
Table 113. South America Oligodendroglioma Treatment Sales Market Share by Countries (2015-2020)
Table 114. South America Oligodendroglioma Treatment Revenue by Countries (2015-2020) (USD Million)
Table 115. South America Oligodendroglioma Treatment Revenue Market Share by Countries (2015-2020)
Table 116. Middle East & Africa Oligodendroglioma Treatment Sales by Countries (2015-2020) (K Pcs)
Table 117. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Countries (2015-2020)
Table 118. Middle East & Africa Oligodendroglioma Treatment Revenue by Countries (2015-2020) (USD Million)
Table 119. Middle East & Africa Oligodendroglioma Treatment Revenue Market Share by Countries (2015-2020)
Table 120. Global Oligodendroglioma Treatment Sales by Type (2015-2020) (K Pcs)
Table 121. Global Oligodendroglioma Treatment Sales Share by Type (2015-2020)
Table 122. Global Oligodendroglioma Treatment Revenue by Type (2015-2020) (USD Million)
Table 123. Global Oligodendroglioma Treatment Revenue Share by Type (2015-2020)
Table 124. Global Oligodendroglioma Treatment Sales by Application (2015-2020) (K Pcs)
Table 125. Global Oligodendroglioma Treatment Sales Share by Application (2015-2020)
Table 126. Global Oligodendroglioma Treatment Sales Forecast by Regions (2021-2025) (K Pcs)
Table 127. Global Oligodendroglioma Treatment Market Share Forecast by Regions (2021-2025)
Table 128. Global Oligodendroglioma Treatment Sales Forecast by Type (2021-2025) (K Pcs)
Table 129. Global Oligodendroglioma Treatment Market Share Forecast by Type (2021-2025)
Table 130. Global Oligodendroglioma Treatment Sales Forecast by Application (2021-2025)
Table 131. Global Oligodendroglioma Treatment Market Share Forecast by Application (2021-2025)
Table 132. Direct Channel Pros & Cons
Table 133. Indirect Channel Pros & Cons
Table 134. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Oligodendroglioma Treatment Picture
Figure 2. Global Sales Market Share of Oligodendroglioma Treatment by Type in 2019
Figure 3. Alisertib Picture
Figure 4. Bevacizumab Picture
Figure 5. CDX-1401 Picture
Figure 6. Dasatinib Picture
Figure 7. DCVax-L Picture
Figure 8. IMA-950 Picture
Figure 9. Others Picture
Figure 10. Oligodendroglioma Treatment Sales Market Share by Application in 2018
Figure 11. Clinic Picture
Figure 12. Hospital Picture
Figure 13. ASCs Picture
Figure 14. Global Oligodendroglioma Treatment Market Status and Outlook (2015-2025) (USD Million)
Figure 15. United States Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Canada Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Mexico Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Germany Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 19. France Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 20. UK Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Russia Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Italy Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 23. China Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Japan Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Korea Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 26. India Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Southeast Asia Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Australia Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 29. Brazil Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Egypt Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Saudi Arabia Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 32. South Africa Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Turkey Oligodendroglioma Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 34. Global Oligodendroglioma Treatment Sales Market Share by Manufacturer in 2019
Figure 35. Global Oligodendroglioma Treatment Revenue Market Share by Manufacturer in 2019
Figure 36. Top 3 Oligodendroglioma Treatment Manufacturer (Revenue) Market Share in 2019
Figure 37. Top 6 Oligodendroglioma Treatment Manufacturer (Revenue) Market Share in 2019
Figure 38. Key Manufacturer Market Share Trend
Figure 39. Global Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 40. Global Oligodendroglioma Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 41. Global Oligodendroglioma Treatment Revenue Market Share by Regions (2015-2020)
Figure 42. Global Oligodendroglioma Treatment Revenue Market Share by Regions in 2018
Figure 43. North America Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
Figure 44. Europe Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
Figure 46. South America Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
Figure 47. Middle East & Africa Oligodendroglioma Treatment Sales and Growth Rate (2015-2020)
Figure 48. North America Oligodendroglioma Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 49. North America Oligodendroglioma Treatment Sales Market Share by Countries (2015-2020)
Figure 50. North America Oligodendroglioma Treatment Sales Market Share by Countries in 2018
Figure 51. North America Oligodendroglioma Treatment Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 52. North America Oligodendroglioma Treatment Revenue Market Share by Countries in 2018
Figure 53. United States Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Canada Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Mexico Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 56. Europe Oligodendroglioma Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 57. Europe Oligodendroglioma Treatment Revenue Market Share by Countries (2015-2020)
Figure 58. Europe Oligodendroglioma Treatment Revenue Market Share by Countries in 2019
Figure 59. Germany Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. UK Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. France Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Russia Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Italy Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 64. Asia-Pacific Oligodendroglioma Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 65. Asia-Pacific Oligodendroglioma Treatment Sales Market Share by Regions 2019
Figure 66. Asia-Pacific Oligodendroglioma Treatment Revenue Market Share by Regions 2019
Figure 67. China Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Japan Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. Korea Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. India Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. Southeast Asia Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 72. South America Oligodendroglioma Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. South America Oligodendroglioma Treatment Sales Market Share by Countries in 2019
Figure 74. South America Oligodendroglioma Treatment Revenue Market Share by Countries in 2019
Figure 75. Brazil Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Argentina Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 77. Middle East and Africa Oligodendroglioma Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 78. Middle East and Africa Oligodendroglioma Treatment Sales Market Share by Countries in 2019
Figure 79. Middle East and Africa Oligodendroglioma Treatment Revenue Market Share by Countries (2015-2020)
Figure 80. Middle East and Africa Oligodendroglioma Treatment Revenue Market Share by Countries in 2019
Figure 81. Saudi Arabia Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Egypt Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. Turkey Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. South Africa Oligodendroglioma Treatment Sales and Growth Rate (2015-2020) (K Pcs)
Figure 85. Global Oligodendroglioma Treatment Sales and Growth Rate (2021-2025) (K Pcs)
Figure 86. Global Oligodendroglioma Treatment Revenue and Growth Rate (2021-2025) (USD Million)
Figure 87. North America Sales Oligodendroglioma Treatment Market Forecast (2021-2025) (K Pcs)
Figure 88. Europe Sales Oligodendroglioma Treatment Market Forecast (2021-2025) (K Pcs)
Figure 89. Asia-Pacific Sales Oligodendroglioma Treatment Market Forecast (2021-2025) (K Pcs)
Figure 90. South America Sales Oligodendroglioma Treatment Market Forecast (2021-2025) (K Pcs)
Figure 91. Middle East & Africa Sales Oligodendroglioma Treatment Market Forecast (2021-2025) (K Pcs)
Figure 92. Sales Channel: Direct Channel vs Indirect Channel
軟骨無形成症治療の世界市場 2020年 Market Overview The global Achondroplasia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Achondroplasia Treat…- バーキットリンパ腫治療の世界市場 2020年 Market Overview The global Burkitt Lymphoma Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 2.3% in the forecast period of 2020 to 2025 and will expected to reach USD 799.1 million by 2025, from USD 728.9 million in 2019. The Burkitt Lym…
- 酒さ治療の世界市場 2020年 Market Overview The global Rosacea Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.1% in the forecast period of 2020 to 2025 and will expected to reach USD 1721.7 million by 2025, from USD 1526 million in 2019. The Rosacea Treatment ma…
- グロボイド細胞白質ジストロフィー治療の世界市場 2020年 Market Overview The global Globoid Cell Leukodystrophy Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Globoid…
- 水腎症治療の世界市場 2020年 Market Overview The global Hydronephrosis Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Hydronephrosis Treat…